IMUC (EOM Pharmaceutical Holdings) Days Payable: 0.00 (As of Jun. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is EOM Pharmaceutical Holdings Days Payable?

EOM Pharmaceutical Holdings IMUC Days Payable is 0.00 as of Jun. 2018.

EOM Pharmaceutical Holdings's average Accounts Payable for the three months ended in Jun. 2018 was $0.60 Mil. EOM Pharmaceutical Holdings's Cost of Goods Sold for the three months ended in Jun. 2018 was $0.00 Mil.

The historical rank and industry rank for EOM Pharmaceutical Holdings's Days Payable or its related term are showing as below:

IMUC's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.36
* Ranked among companies with meaningful Days Payable only.

EOM Pharmaceutical Holdings's Days Payable stayed the same from Jun. 2017 (0.00) to Jun. 2018 (0.00). stayed the same

EOM Pharmaceutical Holdings Days Payable Historical Data

* Premium members only.

The historical data trend for EOM Pharmaceutical Holdings's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EOM Pharmaceutical Holdings Days Payable Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IMUC vs MNTMD, RTTR, BZYR: Days Payable Comparison

For the Biotechnology subindustry, EOM Pharmaceutical Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EOM Pharmaceutical Holdings Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's Days Payable distribution charts can be found below:

* The bar in red indicates where EOM Pharmaceutical Holdings's Days Payable falls into.


EOM Pharmaceutical Holdings Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

EOM Pharmaceutical Holdings's Days Payable for the fiscal year that ended in Dec. 2017 is calculated as

Days Payable (A: Dec. 2017 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2016 ) + Accounts Payable (A: Dec. 2017 )) / count ) / Cost of Goods Sold (A: Dec. 2017 )*Days in Period
=( (1.342 + 1.775) / 2 ) / 0*365
=1.5585 / 0*365
=N/A

EOM Pharmaceutical Holdings's Days Payable for the quarter that ended in Jun. 2018 is calculated as:

Days Payable (Q: Jun. 2018 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Mar. 2018 ) + Accounts Payable (Q: Jun. 2018 )) / count ) / Cost of Goods Sold (Q: Jun. 2018 )*Days in Period
=( (1.125 + 0.084) / 2 ) / 0*365 / 4
=0.6045 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
EOM Pharmaceutical Holdings (IMUC) has a Days Payable of 0.00 as of Jun. 2018. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on EOM Pharmaceutical Holdings and its competitors.
Is EOM Pharmaceutical Holdings' Days Payable too high?
EOM Pharmaceutical Holdings' current Days Payable is 0.00.
How does EOM Pharmaceutical Holdings' Days Payable compare to MNTMD and RTTR?
EOM Pharmaceutical Holdings' Days Payable of 0.00 can be compared against companies in the Biotechnology industry. The industry median Days Payable is 113.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on EOM Pharmaceutical Holdings and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EOM Pharmaceutical Holdings's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EOM Pharmaceutical Holdings stock overvalued right now?
EOM Pharmaceutical Holdings (IMUC) has a current Days Payable of 0.00. The current Days Payable is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For EOM Pharmaceutical Holdings (IMUC), the current Days Payable is 0.00 as of Jun. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EOM Pharmaceutical Holdings Business Description

Address 136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its products have been approved in the U.S., rheumatoid arthritis, and inflammatory conditions of the gastrointestinal tract such as Crohn's Disease and Ulcerative Colitis as well as various retina disorders characterized by a breakdown of the blood-retinal barrier such as diabetic retinopathy, Aged related macular degeneration and retinal vein occlusion among others. Its pipeline includes its compound EOM613, an investigational novel dynamically dual-acting immunomodulator.